Consensus Axsome Therapeutics, Inc.

Stocks

AXSM

US05464T1043

Pharmaceuticals

Market Closed - Nasdaq 04:00:00 05/09/2026 HKT			5-day change	1st Jan Change
206.68 ^USD	-0.80%		+3.85%	+13.16%

09-04	Axsome Therapeutics Insider Sold Shares Worth $2,086,500, According to a Recent SEC Filing	MT
09-01	Axsome Therapeutics' Auvelity Could Drive Revenue Beats After Launch in Alzheimer's Agitation, RBC Says	MT

Evolution of the Average Target: Axsome Therapeutics, Inc.

Evolution of the Target Price: Axsome Therapeutics, Inc.

Changes in Analyst Recommendations: Axsome Therapeutics, Inc.

317ca3feb5626d964.0DycRyohG9X0bvZxuGFvrbI4a3pAUgmpDXLUBx-P8TU.41r-AR92brqOKocJ2ygkwMFSUxY4OTrPPiiwQ0_Jsmazc9UPb3FhmJAguw~73de531b8ea0b9f565a35368ab1165e2

Analysts' recommendations: Axsome Therapeutics, Inc.

09-01	Axsome Therapeutics' Auvelity Could Drive Revenue Beats After Launch in Alzheimer's Agitation, RBC Says	MT
08-12	UBS Adjusts Price Target on Axsome Therapeutics to $280 From $259, Keeps Buy Rating	MT
08-12	Mizuho Adjusts PT on Axsome Therapeutics to $316 From $306, Keeps Outperform Rating	MT
08-11	Axsome's Auvelity Strength Expected to Drive H2 Revenue Growth, RBC Says	MT
08-11	Morgan Stanley Adjusts Axsome Therapeutics PT to $251 From $242, Keeps Equalweight Rating	MT
08-11	RBC Adjusts PT on Axsome Therapeutics to $297 From $304, Maintains Outperform Rating	MT
07-31	Mizuho Trims Price Target on Axsome Therapeutics to $306 From $310, Keeps Outperform Rating	MT
07-21	BMO Capital Initiates Axsome Therapeutics at Outperform With $310 Price Target	MT
07-07	RBC Capital Adjusts Axsome Therapeutics Price Target to $304 From $302, Maintains Outperform Rating	MT
05-28	Axsome Sees Auvelity Momentum, Alzheimer's Agitation Approval Driving Growth Outlook, Oppenheimer Says	MT
05-05	B. Riley Adjusts Price Target on Axsome Therapeutics to $300 From $230, Maintains Buy Rating	MT
05-05	Mizuho Adjusts Price Target on Axsome Therapeutics to $310 From $228, Maintains Outperform Rating	MT
05-05	RBC Raises Price Target on Axsome Therapeutics to $302 From $242, Keeps Outperform Rating	MT
05-04	U.S. research roundup - Alphabet, Colgate-Palmolive, Welltower	RE
05-04	Deutsche Bank Adjusts Axsome Therapeutics PT to $281 From $245, Maintains Buy Rating	MT
04-30	Mizuho Keeps Price Target on Axsome Therapeutics to $228, Maintains Outperform Rating	MT
04-30	Mizuho Adjusts Price Target on Axsome Therapeutics to $228 From $230, Maintains Outperform Rating	MT
04-28	Mizuho Securities Adjusts Axsome Therapeutics Price Target to $228 From $230, Maintains Outperform Rating	MT
04-21	Axsome Therapeutics Facing 'Attractive Setup' Ahead of Auvelity's Label Expansion Decision, Oppenheimer Says	MT
04-10	Axsome Therapeutics Upside Tied to Auvelity FDA Decision, $2 Billion Sales Opportunity Seen, UBS Says	MT
04-10	UBS Adjusts Axsome Therapeutics Price Target to $259 From $251, Maintains Buy Rating	MT
04-07	RBC Capital Adjusts Price Target on Axsome Therapeutics to $221 From $222, Maintains Outperform Rating	MT
03-14	Axsome Still Offers 'Compelling' Core Story, RBC Says	MT
02-24	UBS Adjusts Axsome Therapeutics Price Target to $251 From $248, Maintains Buy Rating	MT
02-24	RBC Raises Price Target on Axsome Therapeutics to $222 From $219, Keeps Outperform Rating	MT

More recommendations

Biopharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	AXSOME THERAPEUTICS, INC.					+38.1%
	REGENERON PHARMACEUTICALS, INC.					+1.54%
	CSL LIMITED					-2.77%
	MODERNA, INC.					-19.96%
	SAMSUNG BIOLOGICS CO.,LTD.					+35.97%
	UCB					+35.33%
	BIOGEN INC.					+7.26%
	INCYTE CORPORATION					+0.78%
	INNOVENT BIOLOGICS, INC.					+25.51%
	SWEDISH ORPHAN BIOVITRUM AB					+9.41%
	Average					+13.12%
	Weighted average by Cap.					+8.97%